ABSTRACT
INTRODUCTION
Bronchopulmonary dysplasia (BPD) is the chronic lung disease that follows ventilator and oxygen therapy for acute respiratory failure after premature birth (10, 38) . Despite improved perinatal care over the past decade, the incidence of BPD remains high, with nearly 60% of surviving premature infants developing chronic lung disease (24) . BPD is characterized by decreased alveolarization, impaired vascular growth and in some cases, progressive pulmonary hypertension (10.21.24.25) . Although hyperoxia, inflammation, infection and ventilator-induced lung injury are associated with the development of BPD, the exact mechanisms that disrupt lung growth in premature infants and cause persistent abnormalities in lung structure are poorly understood. Recently, experimental studies have shown that inhibition of angiogenesis decreases alveolarization in infant rats, suggesting that normal angiogenesis is necessary for alveolarization and that disruption of the developing pulmonary vasculature can lead to the features of BPD (23.31).
However, mechanisms that regulate and link vascular and alveolar growth in the developing lung are still poorly understood. VEGF (vascular endothelial growth factor) is an endothelial cell-specific mitogen and survival factor, which stimulates angiogenesis (43) and protects endothelial cells against injury (14) . Expression of VEGF mRNA and protein are localized to distal airway epithelial cells in the midtrimester human fetal lung, suggesting that VEGF plays a critical role in the regulating epithelial-endothelial interactions early during lung 4 LCMP-00291-2003.R2 development (3.46) . Experimental studies have previously demonstrated decreased lung VEGF expression in the rabbit and primate models of BPD (34, 35) . More recently, clinical studies have shown that VEGF mRNA and protein and VEGF receptors are decreased in the lungs of infants dying with BPD, further suggesting that decreased VEGF activity may contribute to the development of BPD (9) . Furthermore, experimental studies demonstrate that, inhibition of VEGF receptors impairs alveolarization, decreases vascular growth and causes pulmonary hypertension in infant rats (23, 31) . However, mechanisms that impair lung growth and cause pulmonary hypertension following disruption of VEGF signaling are unclear.
Recent studies have demonstrated that endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) play an important role in VEGF-induced angiogenesis in the systemic circulation and tumors (37, 40, 50) . VEGF can upregulate eNOS mRNA, protein and activity and increase NO production in human and bovine vascular endothelial cells in vitro (98, 40) . In addition, inhibition of nitric oxide synthase activity blocks VEGFinduced angiogenesis in vitro (5, 36, 39) and in vivo (19, 40) . Moreover, VEGF-induced angiogenesis is impaired in mice with a genetic deficiency in eNOS (44) . More recent studies have shown that eNOS-deficient neonatal mice are more susceptible to impaired alveolarization and lung vascular growth following exposure to mild hypoxia (6) .
Similarly, inhibition of NOS activity decreases branching morphogenesis in fetal rat lungs and post-pneumonectomy lung growth in adults (32, 49) . Overall, these studies suggest that VEGF induces angiogenesis through increased expression of NOS and that NO production may play an important role in lung growth during development. However, whether impaired VEGF signaling downregulates eNOS expression and decreases NO production in the developing lung is unknown.
Therefore we hypothesize that VEGF regulates pulmonary angiogenesis and lung growth through NO-dependent mechanisms and that disruption of VEGF signaling decreases eNOS expression and NO production in the developing lung, which may contribute to impaired lung growth and pulmonary hypertension. To test this hypothesis, we first determined whether neonatal treatment with a VEGF receptor inhibitor decreases eNOS expression and NO production. To further determine the potential role of impaired VEGF-NO signaling on alveolar and vascular growth in the developing lung, we determined whether prolonged treatment with inhaled NO improves lung growth and decreases pulmonary hypertension in infant rats after VEGF receptor inhibition. We report that early disruption of VEGF receptor activity downregulates lung eNOS expression, and that treatment with low doses of inhaled NO attenuates pulmonary hypertension and improves lung growth in this experimental model of BPD.
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MATERIALS AND METHOD

Animals
All procedures and protocols were approved by the Animal Care and Use Committee at the University of Colorado Health Sciences Center. Pregnant Sprague-Dawley rats (SDR) were purchased from Charles River Laboratories (Wilmington, MA) and maintained in room air at Denver's altitude (1600 meters; barometric pressure, 630 mmHg; inspired oxygen tension, 122 mmHg) for at least 1 week before giving birth. Animals were fed ad libitum and exposed to day-night cycles alternatively every 12h. Rats were sacrificed with an intraperitoneal injection of pentobarbital sodium (0.3 mg/g body wt; Fort Dodge animal Health, Fort Dodge, IA).
Study Design
This study includes 2 basic protocols. In protocol 1, we first determined whether treatment of neonatal rats with a VEGF receptor inhibitor impaired lung eNOS expression during lung development, and whether this reduction in NO production was sustained throughout infancy. In the second protocol, we studied the effects of low dose inhaled NO therapy on pulmonary hypertension and lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. The study protocols are described below.
Protocol 1: to determine whether neonatal treatment with a VEGF receptor inhibitor reduces lung eNOS expression and NO production in the developing lung.
LCMP-00291-2003.R2
The VEGF receptor inhibitor SU5416 was obtained from Calbiochem (San Diego, CA).
Our selection of a treatment dose for SU5416 of 20 mg/kg was based on our previous study in which a single dose of SU-5416 in newborn rats caused pulmonary hypertension and impaired lung growth in infant rats (31) . In this study, 3 day-old rats received a single dose of SU5416 (20 mg/kg) or its vehicle (carboxymethyl cellulose: CMC) by subcutaneous injection. Litters were divided equally between SU5416 treated and vehicle controls and rats were raised in room air at Denver's altitude. Rats from each group were killed for studies at 5 days, 6 days, 7 days and 2 wk of ages. We studied 4 -8 rats at each time point for morphometric studies and western blot analysis.. Studies included assessment of pulmonary hypertension (by measuring right ventricular hypertrophy, (RVH)) and western blot analysis to assay lung protein expression for eNOS, VEGF receptor-2 (VEGFR-2 or kinase insert domain-containing receptor/fetal liver kinase-1 (KDR)), and platelet endothelial cell adhesion molecule-1 (PECAM). In addition, NOx was measured in isolated perfused lungs in 2 wk-old rats after SU5416 (n = 5 animals) and vehicle treatment (n = 6 animals) in order to determine NO production. In addition, TUNEL assay was performed at 2 weeks in order to detect cells undergoing apoptosis from control and SU5416-treated rats. placed in a Plexiglas chamber and exposed to a mix of room air and inhaled NO (10 ppm). O2, NO and NO2 levels were monitored with an iNO Vent controller (iNO Therapeutics, Clinton, NJ) with the exhaust directed into an outside air vent at 10 liters per minute. Eight to twelve animals were studied within each of the 4 study groups. At 3 wk of age, animals were killed for studies of pulmonary hypertension (by measuring right ventricular hypertrophy), pulmonary vascular structure and growth (by measuring pulmonary artery wall thickness and pulmonary artery density) and alveolarization (by measuring radial alveolar count).
Study Measurements Right ventricular hypertrophy (RVH).
At autopsy, the heart was resected through a midline sternostomy. The right ventricle (RV) and left ventricle plus septum (LV+S) were dissected and weighed, and the ratio of RV to LV+S weight was determined as an index of RVH. was centrifuged at 1500 x g at 4°C for 10 min to remove cell debris. Lung homogenates (25 µg) were separated by SDS-PAGE and then transferred to nitrocellulose membranes by electroblotting. Blots were blocked overnight at 4°C in 5% of nonfat dried milk (for eNOS and VEGFR-2) or 5% BSA (for PECAM). Immunodetection was performed with the primary antibody diluted in blocking buffer for 1 h at room temperature. After the blots were washed to remove unbound antibody, a secondary antibody ((horseradish peroxidase-conjuated antimouse (eNOS), anti-rabbit (VEGFR-2), or anti-goat (PECAM)) was diluted in blocking buffer (1:10,000) and applied for 30-60 min. After three washes, ECL Plus detection (Amersham, Piscataway, NJ) was performed. We initially determined the accuracy and consistency of the protein loads for each gel by Ponceau S staining prior to applying the different antibodies. In addition, each gel was stripped and re-probed with ß-actin for use as a housekeeping protein in order to compare expression between samples. The experiments were performed with at least 5 animals per study group, and data represents at least 3 different experiments.
Western blot analysis for eNOS, KDR and PECAM.
[NOx] in lung perfusate. After anesthesia with pentobarbital sodium, a thoracotomy was performed and 100 units of heparin were injected into the right ventricle. The lung was ventilated with humidified gas mixture (21% O 2 , 5% CO 2 and balance N2) at 60 breaths/min, an inspiratory pressure of 9 cm H2O, and an end-expiratory pressure of 2 cm H2O, with a Harvard rodent ventilator. The right ventricle was opened, and a 18-gauge blunt-tipped catheter was placed in the main pulmonary artery. After placement of a similar catheter in the left ventricle, the lung was perfused by a peristaltic pump at 0. Morphometric analysis. Analysis of each section was carried out in a blinded fashion.
Wall thickness of small pulmonary arteries was measured on pulmonary arteries accompanying the terminal or respiratory bronchioles. At least 10 pulmonary arteries were measured for each animal. Arterial wall thickness and external diameter were measured using a Zeiss Interactive Digital Analysis System on hematoxylin and eosinstained lung sections as previously described (2) . The percent medial thickness of an artery was calculated by the following formula: (2 x medial thickness x 100)/external diameter. Pulmonary artery density was determined by counting barium-filled arteries per high-power field (x200 magnification). Alveolarization was assessed by the radial alveolar count (RAC) of Emery and Mithal as described (11) . Respiratory bronchioles were identified as bronchioles lined by epithelium in one part of the wall (42) . From the center of the respiratory bronchiole, a perpendicular was dropped to the edge of the acinus connective tissue or septum or pleura), and the number of septa intersected by this line was counted. At least 15 counts were performed for each animal.
Statistical Analysis
Statistical comparison was made using analysis of variance and Fisher's protected least significant different test and the Statview software package (Abacus Concepts, Berkeley, CA). Data are presented as mean + SE. Differences were considered significant at p < 0.05.
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RESULTS
Protocol 1: to determine whether neonatal treatment with a VEGF receptor
inhibitor reduces lung eNOS expression and NO production in the developing lung.
In comparison with the vehicle-treated control rats, the ratio of RV/LV+S was greater after neonatal treatment with SU5416 throughout the study period. The ratio of RV/LV+S was 23% greater after SU5416 treatment than controls at day 5 of age ( p < 0.05), and progressively increased through day 14 of age (at day 7, 143% of controls, p < 0.05; at day 14, 169% of controls, p < 0.01) ( In comparison with vehicle controls, the SU5416-treated rats had a 56% increase in the ratio of RV/LV+S at 3 wk of age (p < 0.05; Fig. 5 ). Prolonged treatment with inhaled NO (10 ppm) markedly reduced the ratio of RV/LV+S to values measured in CMC control animals at 3 wk of age (p < 0.05; Fig.5 ).
Barium arteriograms illustrate the reduction in the perfusion of small pulmonary arteries after SU5416 treatment (Fig. 6 ). As shown, the background haze is reduced after SU5416
treatment. Prolonged treatment with inhaled NO (10 ppm) increased perfusion of the distal pulmonary arteries.
In comparison with controls, wall thickness of small pulmonary arteries (external diameter between 20-50 µm) was increased by 116% after SU5416 treatment at 3 wk of age (p < 0.05; Fig. 7 ). Following treatment with inhaled NO reduced arterial wall thickness by 35% at 3 wk of age, compared with those SU5416-treated and raised in room air (p < 0.05; Fig. 7 ).
SU5416-treated rats had a 59% reduction in pulmonary artery density at 3 wk of age, in comparison with controls (p < 0.05; Fig. 8 ). As shown, treatment with inhaled NO increased pulmonary artery density by 107%, in comparison with SU5416-treateed animals (p < 0.05; Fig. 8 ).
In addition, SU5416 treatment reduced RAC by 44% from control values at 3 wk of age (p < 0.05; Fig. 9 ). In comparison with the SU5416 treatment group, inhaled NO increased
RACs by 54% at 3 wk of age (p < 0.05).
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DISCUSSION
We found that neonatal treatment with SU5416, a VEGF receptor inhibtor, caused progressive RVH, decreased vessel density and reduced alveolarization in infant rats. We further report that VEGF receptor inhibition decreased lung eNOS protein expression, and that despite the recovery of lung eNOS protein content over time, NOx production was decreased in isolated perfused lungs from infant rats at day 14. In addition, we found that prolonged inhaled NO therapy prevented RVH, reduced wall thickness of small pulmonary arteries, and increased artery density and radial alveolar counts in the infant rats that were treated with SU5416 in newborn period. Overall, our study demonstrates that transient disruption of VEGF signaling in the neonates specifically downregulates lung eNOS expression and decreases lung NO bioavailability in infant rats, which likely contribute to the development of pulmonary hypertension and impaired lung growth.
These findings collectively support our hypotheses that VEGF regulates angiogenesis and lung growth at least partly through NO-dependent mechanisms in the newborn, and that early disruption of VEGF signaling decreases eNOS expression and NO production, which contributes to impaired lung growth and pulmonary hypertension throughout infancy.
This report directly demonstrates that neonatal inhibition of VEGF activity reduces lung eNOS expression and decreases lung NO bioavailability, and impairs distal lung growth Whether decreased eNOS expression and NO production due to altgered VEGF activity plays a major role in the pathogenesis of human BPD requires further study, but is consistent with the findings among these diverse animal models of BPD.
Moreover, this is the first report demonstrating that inhaled NO preserves normal lung growth and prevents pulmonary hypertension after disruption of VEGF signaling. This study indicates that prolonged therapy with inhaled NO can enhance alveolarization and vascular growth in the infant rats susceptible to disrupted lung growth. Our results suggest that inhaled NO therapy may remarkably prevent development of BPD by improving lung growth in the high-risk premature infants.
Past studies have shown that eNOS expression and NO production increase during LCMP-00291-2003.R2 development in the fetal lung (38, 45, 46) . In contrast, eNOS protein is decreased in experimental models of BPD, including chronically ventilated preterm lambs and baboons (4, 33) . Similarly, previous studies have shown abundant VEGF mRNA and protein expressed in the normal fetal lung (3, 47) , but lung VEGF expression is consistently decreased in studies of BPD (9, 29, 34, 35) . Although past studies showed that VEGF can upregulate eNOS expression and augment NO production in vitro (40, 49) and Although eNOS activity has been primarily studied and considered with regard to its effects on vascular tone and structure, recent studies suggest that NO may further modulate vascular growth and alveolarization (6, 32) and branching morphogenesis in the early fetus (49) . Overall, these results along with previously published studies suggest a critical role of VEGF-NO signaling during lung growth and development, and that VEGF signaling may regulate alveolar and vascular growth through modulating eNOS LCMP-00291-2003.R2
expression and NO production.
Inhaled nitric oxide has been demonstrated to be an effective treatment for term infants with persistent pulmonary hypertension, but its role in managing preterm infants is still controversial. As a pulmonary vasodilator, inhaled NO was expected to improve oxygenation in premature infants with BPD, in whom there may be coexisting pulmonary hypertension (1, 8) . Inhaled NO showed modest improvement in oxygenation in infants with established BPD by reducing ventilation-perfusion mismatch (7) . In animal studies, inhaled NO reduces hyperoxia-induced lung injury, suggesting that NO may protect the developing lung against predisposing factors of BPD (18, 20, 22, 36) . Early treatment with inhaled NO decreased ventilator days in survivors of premature infants with acute respiratory failure (28) , suggesting that inhaled NO may decrease the risk of BPD. In this study, inhaled NO is demonstrated to preserve normal growth of the developing lung in an experimental model with structural and functional features of BPD. In the present study, inhaled NO therapy was initiated immediately after VEGF receptor inhibition in the newborn rats, suggesting that early treatment might be required for effectively preserving lung growth to prevent BPD in the high-risk premature neonates.
The mechanisms by which inhaled NO improves lung growth after VEGF receptor inhibition are unknown. Possibilities include decreased oxidant stress (17.18) or apoptosis (20, 26, 48) , decreased inflammation (20, 27) or improved gas exchange (14, 41) .
Alternatively, NO may promote vascular growth and alveolarization by direct effect on LCMP-00291-2003.R2
angiogenesis (5,6,14.16,19,23,37,40,50) . Further studies are needed to determine the mechanisms of NO effects in this model.
We conclude that transient disruption of VEGF signaling in the newborn rats downregulates eNOS expression and decreases NO bioavailability in the infant rat lungs, which may contribute to impaired lung growth and pulmonary hypertension in this experimental model of BPD. We speculate that VEGF-NO pathway regulates alveolarization and angiogenesis, and that NO is required for achieving normal lung development. We suggest that early intervention with prolonged therapy of low-dose inhaled NO may prevent BPD in high-risk premature infants. 
